Recent studies have revealed that long noncoding RNAs (lncRNAs) are connected with pathogenesis of neurodegenerative diseases. Additionally, glucocorticoids have fundamental regulatory roles on the immune system, and act as potent therapeutic compounds for autoimmune and inflammatory diseases. The long noncoding RNA growth arrest-specific 5 (GAS5) which accumulates inside the cells in response to cellular starvation/growth arrest, acts as a potent repressor of the glucocorticoid receptor (GR) through its glucocorticoid response element (GRE).
ultiple sclerosis (MS) is a multifocal chronic progressive inflammatory demyelinating disease of the central nervous system (CNS) that leads to severe neurological disability through axonal degeneration and gliosis (1) . Recent studies have reported that human genome encodes many long non-coding RNAs (lncRNAs) (2) . Table 1 .
Materials and methods

Study design and eligibility criteria
Quantitative real-time PCR (TaqMan®)
Expression levels of GAS5 and its target 
Results
Demographic data of participants
Clinical characteristics, disease duration, and demographic characteristics of RRMS patients and healthy controls are presented in Table 2 . 
GAS5 and NR3C1 expression levels
The expression level of NR3C1 has been compared between MS patients and control group based on age, and sex of the participants. Obtained results are presented in Table 3 . Statistical analysis showed significant up-regulation of NR3C1 gene in MS patients compared with healthy controls (P=0.03), and in male subgroup compared with the corresponding age and sex-matched healthy subjects (P = 0.001). 
